Published on September 29, 2009 at 6:35 AM
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
The Microcyn® Skin and Wound HydroGel for professional use is intended for the management of exudating wounds such as leg ulcers, pressure ulcers, diabetic ulcers, first- and second-degree burns, and mechanically or surgically debrided wounds. It is reimbursable per Medicare HCPCS #A6248. For product and training materials or to order, healthcare professionals can visit http://store.oculusis.com or phone 1-800-759-9305.
The Microcyn® Skin and Wound HydroGel OTC is intended for use by consumers on minor skin abrasions, lacerations, minor irritations and intact skin. The product introduction is being supported by a national advertising campaign that will continue throughout the year. Consumers can order the OTC HydroGel product at www.microcyn.com or by phoning 1-877-572-9583.
The original Microcyn-based solutions, branded as Microcyn Skin & Wound Care with preservatives (HCPCS #A6260) in the United States, Microdacyn60™ in Mexico, Dermacyn™ Wound Care in Europe and China and Oxum in India, has treated over one million patients worldwide without a report of a single serious adverse effect.
“Our new hydrogel products match perfectly with our proprietary Microcyn Skin and Wound Care with preservatives,” said Jim Schutz, COO of Oculus. “Doctors recommend a two-step process when caring for open wounds – clean and protect. Our unique Microcyn solution cleans the skin or wound and our advanced hydrogel provides a barrier against contaminants. Clean and protect using the Microcyn products will improve wound care results. Our straightforward message and cost-effective approach should help reduce healthcare costs in both hospital and home.”
http://www.oculusis.com